Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 112362-50-2 Chemical Structure| 112362-50-2

Structure of Dalfopristin
CAS No.: 112362-50-2

Chemical Structure| 112362-50-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dalfopristin is a semi-synthetic streptogramin antibiotic. Quinupristin/dalfopristin (Q/D) is a valuable alternative antibiotic to vancomycin for the treatment of multi-drug resistant Enterococcus faecium infections.

Synonyms: RP54476

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dalfopristin

CAS No. :112362-50-2
Formula : C34H50N4O9S
M.W : 690.85
SMILES Code : O=S(CCN(CC)CC)([C@H]1[C@@](C(O[C@H]([C@@H](/C=C/C(NC/C=C\C(C)=C\2)=O)C)C(C)C)=O)([H])N(C(C3=COC(CC(C[C@@H]2O)=O)=N3)=O)CC1)=O
Synonyms :
RP54476
MDL No. :MFCD00895414

Safety of Dalfopristin

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301+H311+H331-H315-H319
Precautionary Statements:P261-P264-P270-P271-P280-P301+P310+P330-P302+P352+P312+P361+P364-P304+P340+P311-P305+P351+P338+P337+P313-P403+P233-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Plasmodium falciparum 3D7 1 nM to 100 μM 48 h, 72 h, 96 h, 120 h Evaluation of the inhibitory effect of Dalfopristin on parasite growth, showing IC50 values of 5.18 mg/liter at 48 h and 0.43 mg/liter at 96 h, indicating a delayed death effect Antimicrob Agents Chemother. 2008 Feb;52(2):774-7
Micrococcus luteus DRUG 320 2 mg/L 4 h To determine the concentration of Dalfopristin in serum Antimicrob Agents Chemother. 2002 Jul;46(7):2174-8
Methicillin-resistant Staphylococcus aureus (MRSA) <1 μg/ml Test the activity of Dalfopristin against MRSA, all strains were susceptible to Dalfopristin Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
New Zealand White rabbits Aortic endocarditis model Intramuscular injection 30 mg/kg Every 8 hours for 4 days Evaluate the bactericidal and synergistic activity of Q-D and rifampin combination therapy, results showed the combination was highly bactericidal and synergistic against quinupristin-susceptible strains (HM1054 and RP13) but ineffective against the quinupristin-resistant strain (HM1054R). Antimicrob Agents Chemother. 2001 Apr;45(4):1244-8
New Zealand White rabbits Aortic endocarditis model Intramuscular injection 30 mg/kg Three times a day for 4 days To evaluate the efficacy of Dalfopristin in combination with Gentamicin against MRSA Antimicrob Agents Chemother. 2002 Jul;46(7):2174-8

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01371656 Acute Leukemias of Ambiguous L... More >>ineage Bacterial Infection Diarrhea Fungal Infection Musculoskeletal Complications Neutropenia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies Less << Phase 3 Completed - -
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... More >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Less <<
NCT01371656 - Completed - -
NCT00240747 Gram-Positive Bacterial Infect... More >>ions Less << Phase 3 Terminated - United States, California ... More >> Children's Hospital Oakland, California, United States, 94609 Children's Hospital of Orange County Orange, California, United States, 92868 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27705 United States, Ohio Children's Hospital Cincinnati, Ohio, United States, 45267 The Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Oklahoma Children's Hospital at Saint Francis Tulsa, Oklahoma, United States, 74136 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.45mL

0.29mL

0.14mL

7.24mL

1.45mL

0.72mL

14.47mL

2.89mL

1.45mL

References

 

Historical Records

Categories